A study in humans with coronary artery disease identified the miR-425-3p as significantly upregulated in whole blood of patients with recurrent myocardial infarction after percutaneous coronary intervention, with this association remaining significant after false-discovery rate correction, though it was not significantly different in plasma samples [Onuoha et al. DOI:10.1111/cts.13307]. A study in humans demonstrated that the miR-425-3p is downregulated in peripheral whole blood of responders to duloxetine and placebo in a major depressive disorder cohort, with this finding replicated in independent cohorts and in a mouse model of antidepressant response [Lopez et al. DOI:10.1038/ncomms15497].